Health company Essity stated on Wednesday that it has scaled up the production of its Tork-branded hand sanitizers capacity to meet the increased demand in Europe following the challenges, impact and focus of the COVID-19 pandemic on hand hygiene.
In the Q4 2020, the company will increase its supply capacity of hand sanitizer in Europe to enable the continued high growth of the existing range. Its Professional Hygiene business, under the leading global brand Tork, has seen a steep increase in demand for hand sanitizers in response to new hygiene regulations or customers' desire to provide an additional layer of safety where water and soap are not available.
Based on the research conducted on the company's behalf in July 2020, the hand hygiene is now an integral part of everyday routines and that 74% of people now consider hand hygiene to be more a part of their overall health routine than before the COVID-19 pandemic. About 69% of respondents find hand sanitizers a good complement to washing hands.
With an increase in the sanitizer capacity, the businesses and their employees and customers can offer consistent and reliable access to hand-hygiene products when handwashing is not readily available, concluded the company.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA